Latest news with #INT
&w=3840&q=100)
Business Standard
3 days ago
- Sport
- Business Standard
Inter Milan vs PSG Champions League final LIVE SCORE UPDATES: Inter 0-4 PSG in 2nd half
INT vs PSG LIVE UPDATES: Inter Milan have gone behind with Hakimi and Doue scoring 2 goals against Inter. 1:54 AM Inter vs PSG Champions League final LIVE SCORE UPDATES: Doue makes it 3-0! Another counter and another goal for Desire Doue who virtually kills the tie on the night. A ruthless attack by PSG on the night 1:52 AM Inter vs PSG Champions League final LIVE SCORE UPDATES: Darmian in! Bisseck and Mkhitaryan are subed off for Darmian and Carlos Augusto 1:49 AM Inter vs PSG Champions League final LIVE SCORE UPDATES: Inzaghi not happy with the referee! Inzaghi receives a yellow card for dissent after shouting at the referee. 1:36 AM Inter vs PSG Champions League final LIVE SCORE UPDATES: 2nd half begins! The 2nd half begins with Inter kicking off the 2nd half. Just 45 minutes for the Italian outfits to get into the game now and take it possibly beyind the 90 minutes. 1:19 AM Inter vs PSG Champions League final LIVE SCORE UPDATES: PSG leading 2-0 at half time! It's half time as PSG go into the dressing room with a 2-0 lead after the first 45. 12:43 AM Inter vs PSG Champions League final LIVE UPDATES: PSG ahead! First Published: May 31 2025 | 11:27 PM IST
News18
4 days ago
- Sport
- News18
Paris Saint-Germain Vs Inter Milan Live Football Streaming For UEFA Champions League 2025 final Match: How To Watch PSG Vs INT Coverage On TV And Online
Last Updated: Check out the live streaming details for Paris Saint-Germain vs Inter Milan UEFA Champions League 2025 final to be played at Munich Football Arenain Germany Munich Football Arena in Germany Live Football Streaming For the UEFA Champions League 2025 final Match: Paris Saint-Germain will take on Inter Milan in the UEFA Champions League 2025 final on Saturday, May 31. The ultimate face-off between the two European heavyweights is set to be played at the Munich Football Arena in Germany. PSG aim for their maiden Champions League trophy against an Inter Milan side hoping to grab hold of the prized silverware again after 15 years. The two teams enter the summit clash in high spirits after overcoming the high-pressure semifinal round. While PSG secured their berth in the final by defeating Arsenal 2-1 and 1-0, Inter came out triumphant against Barcelona by winning the second leg fixture 4-3 after playing out an intense draw with three goals apiece in the first encounter. PSG vs INT will be played on May 31, Saturday PSG vs INT will be played at the Munich Football Arenain Germany. PSG vs INT will start at 12:30 AM IST (Sunday, June 1). PSG vs INT will be televised live in India on the Sony Ten 2 and Sony Ten 2 HD TV channels. How do I watch Paris Saint-German vs Inter Milan UEFA Champions League 2025 final live streaming? PSG vs INT will be streamed live on the SonyLiv app in India. What are the Predicted Line-ups for Paris Saint-Germain vs Inter Milan UEFA Champions League 2025 final live game? Paris Saint-German XI: Donnarumma, Hakimi, Marquinhos, Pacho, Mendes, Neves, Vitinha, Fabian Ruiz, Doue, Dembele, Kvaratskhelia First Published: May 31, 2025, 00:31 IST
News18
05-05-2025
- Sport
- News18
Inter Milan Vs Barcelona Live Streaming For UCL 2024-25 Semi-Final Match: When And Where To Watch INT vs BAR Coverage on TV And Online
Last Updated: Check out the live streaming details for Barcelona and Inter Milan Champions League 2024-25 Semi-Final match to be played at San Siro, Milan. Inter Milan vs Barcelona Live Football Streaming For Champions League 2024-25 Semi-Final Match: Barcelona and Inter Milan played out one of the most thrilling Champions League games of this season in the first leg of the semi-finals. Despite conceding two early goals, the Spanish side pulled off a roaring comeback, thanks to an exceptional performance by Lamine Yamal. The 17-year-old winger scored the opening goal for Barcelona a few minutes after Denzel Dumfries doubled the lead for Inter. Yamal almost got his second following a mesmerising solo run, but his shot was tipped onto the top post by Yann Sommer. Ferran Torres finally made it two-all ahead of the first-half whistle. Inter Milan had a great start to the second half, with Dumfries completing his brace to put his team in front in the 63rd minute. Barcelona were on the verge of another heartbreak, but Raphinha once again stepped up to make it level. The Brazilian forward struck a brilliant long-range shot that deflected off Sommer before going into the net. The second leg of the Champions League semi-final between Inter Milan and Barcelona is scheduled for May 7. The iconic San Siro in Milan will host the blockbuster contest at 12:30 AM IST on Wednesday. INT vs BAR will be played on May 7, Wednesday. INT vs BAR will be played at the San Siro in Milan. INT vs BAR will start at 12:30 AM IST. Which TV channels will broadcast Inter Milan vs Barcelona Champions League 2024-25 Semi-Final match? INT vs BAR will be televised on the Sony Sports Network in India. How do I watch Inter Milan vs Barcelona Champions League 2024-25 Semi-Final match live streaming? INT vs BAR will be streamed live on the Sony LIV app and website in India. What are the Predicted Line-ups for Inter Milan vs Barcelona Champions League 2024-25 Semi-Final game? First Published:
Yahoo
27-02-2025
- Business
- Yahoo
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even FREMONT, Calif., February 27, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. Recent Business Highlights Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024; delivered 3,285 total molecular tests for the full year of 2024 compared with 177 in 2023 Submitted for Medicare coverage in early-stage breast cancer Collaborators have submitted manuscripts for publication in peer-reviewed journals for all three Personalis focus indications in breast and lung cancer and IO monitoring, with breast cancer accepted for publication Expanded the number of clinical studies in progress to over 20 Raised $50 million with Merck Sharp & Dohme LLC ("Merck") in a direct investment transaction Signed a multi-year extension with ModernaTX, Inc. ("Moderna") to utilize ImmunoID NeXT for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna Expanded the commercial agreement with Tempus AI, Inc. ("Tempus") to authorize Tempus to sell NeXT Personal® to pharmaceutical and biotechnology companies "In 2024, we executed very well and are starting 2025 confident our strategy is working and we will 'Win in MRD,'" said Chris Hall, Chief Executive Officer and President. "We expanded our partnership with Tempus, presented compelling clinical data at Medical Conferences, and drove testing growth 52% quarter over quarter ending the year with 1,441 molecular tests in the fourth quarter. Also, we announced a long-term commercial collaboration with Moderna and a strategic investment of $50 million from Merck, endorsing our technology platform and capabilities to support our partners' initiatives, and providing a pathway to cashflow break-even." Full Year 2024 Financial Results Compared with 2023 Revenue of $84.6 million for the full year of 2024 compared with $73.5 million, an increase of 15% Revenue from pharma tests and services, enterprise sales, clinical diagnostics, and other customers of $77.2 million for the full year of 2024 compared with $64.1 million, an increase of 20%, despite the expected decrease in revenue from Natera of 20% to $25.4 million for the full year of 2024 Revenue from population sequencing for the VA MVP of $7.4 million for the full year of 2024, compared with $9.4 million, a decrease of 21% Net loss of $81.3 million, and net loss per share of $1.37 based on a weighted-average basic and diluted share count of 59.3 million for the full year of 2024 compared with a net loss of $108.3 million, and net loss per share of $2.25 based on a weighted-average basic and diluted share count of 48.2 million Cash, cash equivalents, and short-term investments of $185.0 million as of December 31, 2024; includes the $50.0 million strategic investment from Merck; reduced cash usage from operations and capital equipment additions in 2024 to $46.8 million, compared with $67.2 million Fourth Quarter 2024 Financial Results Compared with 2023 Revenue of $16.8 million for the fourth quarter of 2024 compared with $19.7 million for the fourth quarter of 2023, a decrease of 15%, primarily due to the expected decline in revenue from Natera and the VA MVP Pharma tests and services, enterprise sales, clinical diagnostics, and other customers of $16.6 million for the fourth quarter of 2024 compared with $18.7 million for the fourth quarter of 2023, a decrease of 11% Population sequencing for the VA MVP of $0.2 million for the fourth quarter of 2024 compared with $1.0 million for the fourth quarter of 2023, a decrease of 78% Net loss of $16.4 million, and net loss per share of $0.23 based on a weighted-average basic and diluted share count of 72.9 million in the fourth quarter 2024 compared with a net loss of $26.6 million, and net loss per share of $0.54 based on a weighted-average basic and diluted share count of 49.6 million in the fourth quarter of 2023 First Quarter and Full Year 2025 Outlook Personalis expects the following for the first quarter of 2025: Total company revenue to be in the range of $17 to $18 million Revenue from pharma tests and services, and all other customers to be in the range of $10 to $11 million Revenue from population sequencing and enterprise sales of approximately $7 million Personalis expects the following for the full year of 2025: Total company revenue in the range of $80 to $90 million Revenue from pharma tests and services, and all other customers in the range of $62 to $64 million Revenue from population sequencing and enterprise sales in the range of $15 to $16 million Revenue from clinical tests reimbursed in the range of $3 to $10 million Gross margin in the range of 21% to 23%, which is lower than the 32% gross margin for the full year of 2024 as we invest to drive clinical usage ahead of reimbursement. Net loss of approximately $85 million Cash usage in the range of $75 to $80 million, which is an increase from the $47 million used in 2024 primarily due to investments in the next phase of our "Win in MRD" strategy, inclusive of growing our test volume, expanding clinical studies, and investing in commercial capabilities to drive growth Webcast and Conference Call Information Personalis will host a conference call to discuss the fourth quarter and full year 2024 financial results, as well as plans for 2025, after market close on Thursday, February 27, 2025, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar can be accessed at A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as "anticipate," "estimate," "expect," "if," "may," "future," "will" or similar expressions. These statements include statements relating to: Personalis' first quarter and full year 2025 financial guidance, the benefits of the collaboration with Moderna and the strategic investment from Merck and the ability of Personalis to support their and other partners' initiatives, and the potential for Personalis to achieve cashflow break-even in the future. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from Moderna, Merck, and VA MVP; the success of Personalis' clinical sales team's and Tempus's sales and marketing efforts; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; Personalis' ability to demonstrate attributes, advantages or clinical validity of the NeXT platform; the rate of adoption and use of the NeXT platform; the expected benefits of Personalis' extended collaboration with Moderna and the strategic investment from Merck; Personalis' ability to obtain Medicare coverage and reimbursement; the benefits of Personalis' investments in growing clinical test volume and its commercial capabilities; the expansion of clinical studies; and Personalis may opportunistically raise additional capital through equity offerings, debt financings, collaborations, or licensing arrangements. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission (SEC) on November 6, 2024 and in its Annual Report on Form 10-K for the year ended December 31, 2024, being filed with the SEC on February 27, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. PERSONALIS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 (unaudited) Revenue (1) $ 16,800 $ 19,675 $ 84,614 $ 73,481 Costs and expenses Cost of revenue 12,250 14,470 57,789 55,273 Research and development 11,494 13,613 48,905 64,776 Selling, general and administrative (2) 11,168 11,524 46,187 49,726 Lease impairment — — — 5,565 Restructuring and other charges — 4,040 — 8,077 Total costs and expenses 34,912 43,647 152,881 183,417 Loss from operations (18,112 ) (23,972 ) (68,267 ) (109,936 ) Interest income 1,631 1,477 5,510 5,901 Interest expense 1 (9 ) (24 ) (110 ) Other income (expense), net (3) 59 (4,075 ) (18,485 ) (4,068 ) Loss before income taxes (16,421 ) (26,579 ) (81,266 ) (108,213 ) Provision for income taxes 4 5 18 83 Net loss $ (16,425 ) $ (26,584 ) $ (81,284 ) $ (108,296 ) Net loss per share, basic and diluted $ (0.23 ) $ (0.54 ) $ (1.37 ) $ (2.25 ) Weighted-average shares outstanding, basic and diluted 72,879,436 49,596,698 59,251,013 48,175,201 (1) Includes related party revenue of $2.0 million for three and twelve months ended December 31, 2024. (2) Includes related party sales and marketing expenses of $0.2 million and $0.5 million for the three and twelve months ended December 31, 2024, respectively. (3) Includes related party other expense of $18.3 million in connection with the change in fair value of Tempus Warrants for the twelve months ended December 31, 2024. PERSONALIS, INC. SUPPLEMENTAL REVENUE INFORMATION (in thousands) Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 (unaudited) Pharma tests and services (1) $ 12,232 $ 11,491 $ 50,939 $ 31,904 Enterprise sales 4,170 7,073 25,364 31,729 Population sequencing 219 1,007 7,430 9,412 Clinical diagnostic 176 33 759 38 Other 3 71 122 398 Total revenue $ 16,800 $ 19,675 $ 84,614 $ 73,481 (1) Includes related party revenue of $2.0 million for the three and twelve months ended December 31, 2024. PERSONALIS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) December 31, 2024 2023 Assets Current assets Cash and cash equivalents $ 91,415 $ 56,984 Short-term investments 93,594 57,195 Accounts receivable, net (1) 8,140 17,730 Inventory and other deferred costs 5,939 10,474 Prepaid expenses and other current assets 3,927 4,361 Total current assets 203,015 146,744 Property and equipment, net 48,274 57,366 Operating lease right-of-use assets 16,453 17,852 Other long-term assets 2,526 3,137 Total assets $ 270,268 $ 225,099 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 6,397 $ 14,920 Accrued and other current liabilities (2) 21,629 23,941 Contract liabilities 3,100 3,288 Short-term warrant liability — 5,085 Total current liabilities 31,126 47,234 Long-term operating lease liabilities 34,882 38,321 Long-term warrant liability — 4,942 Other long-term liabilities (3) 1,303 5,161 Total liabilities 67,311 95,658 Commitments and contingencies Stockholders' equity Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued — — Common stock, $0.0001 par value — 200,000,000 shares authorized; 85,171,146 and 50,480,694 shares issued and outstanding, respectively 9 5 Additional paid-in capital 752,961 598,364 Accumulated other comprehensive loss (23 ) (222 ) Accumulated deficit (549,990 ) (468,706 ) Total stockholders' equity 202,957 129,441 Total liabilities and stockholders' equity $ 270,268 $ 225,099 (1) Includes related party accounts receivable of $2.5 million as of December 31, 2024. (2) Includes related party liabilities of $1.7 million as of December 31, 2024. (3) Includes related party liabilities of $1.2 million as of December 31, 2024. View source version on Contacts Investor Relations Contact:Caroline Cornerinvestors@ 415-202-5678 Media:pr@ Sign in to access your portfolio
